Cargando…
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results
BACKGROUND AND AIM: Long-term treatment with tenofovir disoproxil fumarate (TDF) has demonstrated suppression of viral replication outside of China. This study aims to assess efficacy, resistance and safety of TDF for up to 240 weeks in Chinese patients with chronic hepatitis B virus (HBV) infection...
Autores principales: | Liang, Xieer, Gao, Zhiliang, Xie, Qing, Zhang, Jiming, Sheng, Jifang, Cheng, Jun, Chen, Chengwei, Mao, Qing, Zhao, Wei, Ren, Hong, Tan, Deming, Niu, Junqi, Chen, Shijun, Pan, Chen, Tang, Hong, Wang, Hao, Mao, Yimin, Jia, Jidong, Ning, Qin, Xu, Min, Wu, Shanming, Li, Jun, Zhang, Xinxin, Zhang, Wenyan, Xiong, Cui, Hou, Jinlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529393/ https://www.ncbi.nlm.nih.gov/pubmed/30977033 http://dx.doi.org/10.1007/s12072-019-09943-6 |
Ejemplares similares
-
Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022) -
3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021) -
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023) -
Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023) -
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
por: Liu, Zhihong, et al.
Publicado: (2021)